This antibody has the capacity to activate natural killer (NK) cells and works synergistically with PD-L1 inhibitors, cetuximab or trastuzumab, to augment NK cell-mediated cytotoxicity against tumor cells. This evidence concerns the gene CD274 and neoplasm.